Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast cancer: A retrospective, single institution experience Journal Article
| Authors: | Murthy, R. K.; Raghavendra, A. S.; Hess, K. R.; Fujii, T.; Lim, B.; Barcenas, C. H.; Zhang, H.; Chavez-Mac-Gregor, M.; Mittendorf, E. A.; Litton, J. K.; Giordano, S. H.; Thompson, A. M.; Valero, V.; Moulder, S. L.; Tripathy, D.; Ueno, N. T. |
| Article Title: | Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER-2/neu-positive breast cancer: A retrospective, single institution experience |
| Abstract: | Our findings show the efficacy of pertuzumab and trastuzumab-containing regimens compared with trastuzumab-containing regimens with regard to achieving pathologic complete response in over 900 patients with stage II to III human epidermal growth factor 2 (HER2)-positive breast cancer, emphasizing the effect of incorporating an additional anti-HER2 targeted agent into modern neoadjuvant therapy for HER2-positive breast cancer in clinical practice. Introduction: Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2+) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic complete response (pCR) rate for trastuzumab and pertuzumab (HP)-containing regimens compared with trastuzumab (H)-containing regimens for stage II to III HER2+ BC. Patients and Methods: Patients (n = 977) with stage II to III HER2+ BC who received neoadjuvant HER2-targeted therapy from 2005 to 2016 and underwent definitive breast and axillary lymph node surgery were identified. pCR was defined as ypT0/is, ypN0. Univariate/multivariate logistic regression and the χ2 test for comparing proportions was used for the statistical analysis. Results: The pCR rate was higher for the HP group (n = 170) compared with the H group (n = 807): 59% versus 46% (odds ratio, 1.7; 95% confidence interval, 1.21-2.37; P =.0021). After adjustment for clinically important factors (age, date of diagnosis, stage, tumor grade, nodal status, hormone receptor [HR] status, menopausal status, and chemotherapy backbone) the adjusted odds ratio was 2.25 (95% confidence interval, 1.08-4.73; P =.032). In multivariate analysis, a significant predictor of pCR in both groups included HR status (HR-negative > HR-positive). Conclusion: These results demonstrate that HP-containing regimens yield higher pCR rates compared with H-containing regimens in patients with stage II to III HER2+ BC in clinical practice regardless of chemotherapy backbone. © 2018 Elsevier Inc. |
| Keywords: | chemotherapy; trastuzumab; neoadjuvant; pertuzumab; pathologic complete response |
| Journal Title: | Clinical Breast Cancer |
| Volume: | 18 |
| Issue: | 6 |
| ISSN: | 1526-8209 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-12-01 |
| Start Page: | e1283 |
| End Page: | e1288 |
| Language: | English |
| DOI: | 10.1016/j.clbc.2018.07.008 |
| PROVIDER: | scopus |
| PUBMED: | 30077429 |
| DOI/URL: | |
| Notes: | Clin. Breast Cancer -- Export Date: 2 January 2019 -- Article -- CODEN: CBCLB -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work